EAF Soars 73% on Pricing Inflection: Inside Today's Top EPS Revisions
GrafTech (EAF) surged 73.4% to $12.05 after its Q3 earnings beat and management guided to higher realized pricing in Q4 and 2027. Soluna (SLNH) and XTI Aerospace (XTIA) also posted strong gains of 32.1% and 30.6% respectively, while Genmab (GMAB) and Cosmos Health (COSM) rounded out the top performers with 29.0% and 21.7% advances, all driven by positive EPS estimate revisions.
| Ticker | Sector | Detected | EPS Revision | Gain Since Detection |
|---|---|---|---|---|
| EAF | Industrials | 2026-10-20 | N/A | +73.4% |
| SLNH | Financial | 2026-10-22 | N/A | +32.1% |
| XTIA | Industrials | 2026-10-22 | N/A | +30.6% |
| GMAB | Healthcare | 2026-10-23 | N/A | +29.0% |
| COSM | Healthcare | 2026-10-26 | +14.8pp | +21.7% |
Why did EAF stock jump in October 2026?
EAF jumped 73.4% (from $6.95 to $12.05) after analysts raised its EPS growth estimate to 35.0% on October 20, 2026.
The move accelerated after GrafTech's Q3 earnings beat on October 23, with adjusted loss of $1.21 per share beating the -$1.46 consensus by 17.1%, and revenue of $140.2 million topping estimates by 10.7%. Management guided to a mid-single-digit sequential price increase in Q4 and reaffirmed expectations for meaningfully higher realized pricing in 2027, signaling a pricing inflection. The closure of the high-cost Monterrey plant further supports margin recovery, and the stock has continued to climb as investors bet on the turnaround.
EAF EPS revision history → · Screener snapshot from 2026-10-20 →
FAQ: EAF
Why did EAF stock jump 73% in October 2026?
EAF surged 73.4% from $6.95 to $12.05 after its Q3 earnings beat and management guided to higher realized pricing in Q4 and 2027, driven by a pricing inflection and cost-cutting initiatives.
Is EAF a buy after its 73% rally?
Analysts see further upside as GrafTech expects meaningfully higher realized pricing in 2027 and has closed its high-cost Monterrey plant, though the balance sheet remains leveraged with $9 million EBITDA still not covering interest.
What is EAF's EPS growth estimate for next year?
GrafTech's EPS growth estimate for next year is 35.0%, revised upward on October 20, 2026, reflecting expectations of a pricing recovery and operational improvements.
Why did SLNH stock jump in October 2026?
SLNH jumped 32.1% (from $0.53 to $0.70) after analysts raised its EPS growth estimate to 33.3% on October 22, 2026.
The revision followed Soluna's agreement to develop the Dorothy 3 HPC campus through a joint venture with Applied Digital, which will own 51% and supply financing and construction. Rosenblatt reiterated its Buy rating but cut its price target to $2 from $4, citing lower profitability from the JV structure but implying significant upside from the current price. The stock has rallied as investors focus on the growth potential from AI data center demand and Soluna's early position in the HPC transition.
SLNH EPS revision history → · Screener snapshot from 2026-10-22 →
FAQ: SLNH
Why did SLNH stock jump 32% in October 2026?
SLNH rose 32.1% from $0.53 to $0.70 after its EPS growth estimate was revised to 33.3% and it announced a joint venture with Applied Digital to develop a 50 MW AI data center at its Dorothy 3 site.
What caused Soluna's surge after the Applied Digital joint venture?
The joint venture with Applied Digital for the Dorothy 3 HPC campus, announced on October 22, 2026, drove the surge as it positions Soluna to benefit from AI data center demand, despite Rosenblatt lowering its price target to $2.
Is SLNH a buy after its recent rally?
Rosenblatt maintains a Buy rating with a $2 price target, implying substantial upside from $0.70, though the lowered target reflects reduced profitability from the JV structure.
Why did XTIA stock jump in October 2026?
XTIA jumped 30.6% (from $0.85 to $1.11) after analysts raised its EPS growth estimate to 74.6% on October 22, 2026.
The revision followed XTI Aerospace's preliminary Q3 revenue of $35.3 million, a 9% sequential increase, driven by demand for enterprise drone solutions across public safety, government, and commercial markets. The company also announced a non-binding agreement to restructure $4.5 million of promissory notes on October 29, extending maturities and providing financial flexibility. The stock has benefited from optimism around its revenue growth and restructuring efforts, despite near-term liquidity concerns.
XTIA EPS revision history → · Screener snapshot from 2026-10-22 →
FAQ: XTIA
Why did XTIA stock jump 30% in October 2026?
XTIA rose 30.6% from $0.85 to $1.11 after its EPS growth estimate was revised to 74.6% following preliminary Q3 revenue of $35.3 million and a debt restructuring agreement announced on October 29.
What caused XTI Aerospace's surge after its Q3 revenue report?
XTI Aerospace's preliminary Q3 revenue of $35.3 million, a 9% sequential increase, and the restructuring of $4.5 million in promissory notes improved investor sentiment and drove the surge.
What is XTIA's EPS growth estimate for next year?
XTI Aerospace's EPS growth estimate for next year is 74.6%, revised upward on October 22, 2026, reflecting expected revenue growth and cost reductions.
Why did GMAB stock jump in October 2026?
GMAB jumped 29.0% (from $43.79 to $56.49) after analysts raised its EPS growth estimate to 46.3% on October 23, 2026.
The rally was reinforced by positive Phase 3 results for petosemtamab in head and neck cancer, which reduced the risk of death by 50% versus pembrolizumab alone, announced on October 28. J.P. Morgan upgraded Genmab to Overweight on October 27, raising its price target to DKr3,500 from DKr2,050 and increasing peak sales forecasts for petosemtamab to $5 billion from $2.5 billion. The stock also benefited from broader European market optimism and encouraging colorectal cancer data.
GMAB EPS revision history → · Screener snapshot from 2026-10-23 →
FAQ: GMAB
Why did GMAB stock jump 29% in October 2026?
GMAB surged 29.0% from $43.79 to $56.49 after its EPS growth estimate was revised to 46.3% and positive Phase 3 results for petosemtamab showed a 50% reduction in risk of death in head and neck cancer.
What caused Genmab's stock surge after the cancer trial results?
Genmab's Phase 3 LiGeR-HN1 trial met primary endpoints with a 50% reduction in risk of death, leading to a 16% one-day gain and a J.P. Morgan upgrade with a raised price target of DKr3,500.
Is GMAB a buy after its recent rally?
J.P. Morgan upgraded Genmab to Overweight with a DKr3,500 price target, implying further upside from $56.49, based on petosemtamab's potential $5 billion peak sales.
Why did COSM stock jump in October 2026?
COSM jumped 21.7% (from $0.23 to $0.28) after analysts raised its EPS growth estimate to 146.7% on October 26, 2026, a 14.8 percentage point upward revision.
No company-specific news was found in the window, so the move appears driven by the magnitude of the EPS revision and speculative interest in the healthcare sector. The revision reflects expectations of significant earnings growth, though the stock remains volatile at a low price. The screener caught the revision early, and the market has since confirmed it with a strong price gain.
COSM EPS revision history → · Screener snapshot from 2026-10-26 →
FAQ: COSM
Why did COSM stock jump 21% in October 2026?
COSM rose 21.7% from $0.23 to $0.28 after its EPS growth estimate was revised upward to 146.7% on October 26, 2026, reflecting expectations of substantial earnings growth.
What caused Cosmos Health's surge without news?
The surge was driven by a significant upward EPS estimate revision, from 131.8% to 146.7%, which attracted speculative buying in the absence of company-specific news.
What is COSM's EPS growth estimate for next year?
Cosmos Health's EPS growth estimate for next year is 146.7%, revised upward by 14.8 percentage points on October 26, 2026.
Today's top performers highlight the market's responsiveness to earnings estimate revisions, particularly when paired with positive news catalysts like GrafTech's pricing inflection and Genmab's trial success. The rally in small-cap and biotech names suggests investors are rewarding growth potential and operational turnarounds, even amid broader macroeconomic uncertainties.
How We Identify These Stocks
We track daily changes in forward EPS estimates across thousands of US equities. When a stock's next-year earnings growth estimate is revised upward — confirmed by improvement in current-year estimates — it enters our watchlist. The stocks above were flagged on their detection dates and have since delivered the strongest price returns among all detected stocks.
Explore today's full screener →